SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review

被引：6
|
作者：
Xu, Rong [1 ,2 ]
Lian, Difei [1 ,2 ]
Xie, Yan [1 ,2 ]
Chen, Zhilei [1 ,2 ]
Wang, Yan [1 ,2 ]
Mu, Lin [1 ,2 ]
Wang, Yuan [1 ,2 ]
Zhang, Baoyu [1 ,2 ]
机构：
[1] Capital Med Univ, Lu He Hosp, Ctr Endocrine Metab & Immune Dis, Beijing 100000, Peoples R China
[2] Beijing Key Lab Diabet Res & Care, Beijing 100000, Peoples R China
来源：
FRONTIERS IN BIOSCIENCE-LANDMARK | 2023年 / 28卷 / 07期
关键词：
SGLT-2; inhibitors; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; type; 2; diabetes; TYPE-2; DIABETES-MELLITUS; PPAR-ALPHA/GAMMA AGONIST; GLP-1 RECEPTOR AGONISTS; INSULIN-CLEARANCE; DOUBLE-BLIND; INFLAMMASOME ACTIVATION; HEPATIC STEATOSIS; BARIATRIC SURGERY; OBETICHOLIC ACID; REDUCES FEATURES;
D O I：
10.31083/j.fbl2807134
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Non-alcoholic fatty liver disease (NAFLD) is a group of metabolic liver illnesses that lead to accumulation of liver fat mainly due to excessive nutrition. It is closely related to insulin resistance, obesity, type 2 diabetes, and cardiovascular disease, and has become one of the main causes of chronic liver disease worldwide. At present, there is no specific drug for the treatment of NAFLD; lifestyle interventions including dietary control and exercise are recommended as routine treatments. As a drug for the treatment of type 2 diabetes, sodium-glucose co-transporter type 2 (SGLT-2) inhibitors may also play a beneficial role in the treatment of NAFLD. This article reviews the mechanism of SGLT-2 inhibitors in the treatment of NAFLD.
引用
收藏
页数：12
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [22] Non-alcoholic fatty liver disease
    Smith, Briohny W.
    Adams, Leon A.
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (03) : 97 - 113
  • [23] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [24] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [25] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [26] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [27] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [28] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [29] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [30] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
12345